Provides surgical aesthetic treatments like eye surgery, rhinoplasty, breast augmentation, and liposuction. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
No real growth (2.2% a year). Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
angles, checked one by one.
The 3 that stand out are on screen; the rest are not shown.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $105.6M a year. A small number, but proof the product has real buyers.
A loss of $7.8M against $105.6M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.01. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
The stock trades 100% below its five-year peak.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
The takeaway: PAIYY is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.